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Toxic and Essential Trace Element Content of 
Commonly Administered Pediatric Oral Medications
Robert A. Yokel, BS, PhD; Sarah E. Seger, PharmD; and Jason M. Unrine, BS, PhD
OBJECTIVES The aim of this study was to test the hypothesis that commonly administered pediatric oral 
medications are a significant source of toxic elements. The concentrations of 16 elements were determined 
in 14 frequently used pediatric oral medications.
METHODS Samples were prepared for analysis by dilution or nitric acid microwave-assisted digestion and 
analyzed by inductively coupled plasma mass spectrometry. The intake of each element from administration 
for 1 week of the medication’s maximum recommended daily dose to 6-month-olds was calculated and 
compared to an exposure guideline for that element. Exposure guidelines used for adverse effects were 
minimal risk levels, oral reference dose, permissible or permitted daily exposure, provisional tolerable 
weekly intake, and tolerable upper intake concentrations. Exposure guidelines utilized for desired effect 
were adequate intake and recommended dietary allowance.
RESULTS Intake of the maximum recommended daily dose by 6-month-olds for 1 week would not deliver 
more than the exposure guideline of any of the elements, with the exceptions of chromium in several 
medications and zinc in the pediatric electrolyte solution, if it was consumed for 1 week.
CONCLUSIONS Consumed alone, these frequently administered pediatric oral medications would not deliver 
amounts of toxic elements that exceed established exposure guidelines for adverse effects, nor would most 
significantly contribute to adequate intake of essential elements.
ABBREVIATIONS ICP-MS, inductively coupled plasma mass spectrometry; US FDA, United States Food and 
Drug Administration; USP, United States Pharmacopeia
KEYWORDS aluminum; cadmium; lead; maximum allowable concentration; metals (heavy); oral medications; 
pediatric; recommended dietary allowances; trace elements
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Introduction
Infants are particularly susceptible to metal toxicity 
as a result of their immature organs. When exposed to 
toxic metals, infants exhibit increased gastrointestinal 
absorption, less effective renal excretion, and a less 
effective blood-brain barrier than are associated with 
adults.1 In addition, their low body weight and high food 
consumption per kilogram of body weight put infants at 
risk for developing high concentrations of toxic metals.1 
Numerous agencies, including the World Health Orga-
nization, the US Environmental Protection Agency, the 
National Institutes of Health Office of Dietary Supple-
ments, the US Food and Drug Administration (US FDA), 
and the US Department of Agriculture, have established 
guidelines for the safe intake of potentially toxic ele-
ments. Medications present a potential source of toxic 
metals to infants. The United States Pharmacopeia 
(USP) established limits for elemental impurities in USP 
<232>. In September 2015, the US FDA released Q3D 
Elemental Impurities Guidance for Industry that states 
the permitted daily exposure to impurities of some 
elements in drug products administered by the oral, 
parenteral, and inhalation routes.2
Toxic elements of concern for infant exposure from 
medications include aluminum, cadmium, and lead. 
Because they are not essential for humans, these ele-
ments present a risk with no potential benefit. Although 
the gastrointestinal tract provides a significant barrier to 
oral absorption of many potentially toxic elements, it is 
not a complete barrier. Oral bioavailability of aluminum 
is less than 1%; however, elevated plasma aluminum 
concentrations have been reported3,4 in healthy infants 
given aluminum-containing antacids. Target organs of 
aluminum toxicity are the brain, skeletal system, and 
bone marrow.5,6 Toxicity can be manifested as impaired 
cognitive development and function and in the absence 
of renal function can be manifested in a lethal encepha-
lopathy, a low-turnover bone disease associated with 
osteomalacia, and a microcytic anemia. Oral bioavail-
ability of cadmium is estimated to be 1% to 10% and is 
higher in young animals than in adult animals.7 Cadmium 
is a nephrotoxicant and reproductive toxicant with 
the potential to produce osteomalacia.7 Absorption of 
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water-soluble lead by infants is estimated to be 40% to 
50%, whereas it is 10% or less in adults.8 Lead is a potent 
neurotoxicant that irreversibly affects central nervous 
system development, leading to reduced IQ and learn-
ing disabilities.8,9 Oral bioavailability is factored into the 
risk assessment that generates permissible/permitted 
daily exposures, evidenced by the different exposure 
values for the oral and parenteral routes in USP 232 
and the FDA’s Q3D Elemental Impurities Guidance for 
Industry.2
There is little information on the content of toxic met-
als in medications commonly administered to infants. 
This issue is reviewed in the “Discussion” section. 
This study addresses the information gap related to 
the content of toxic metals in medications commonly 
administered to infants and addresses the hypothesis 
that commonly administered pediatric oral medications 
are a significant source of toxic elements. This was ac-
complished by determining the concentrations of 16 
elements, all having the potential to produce toxicity, 
6 of which are known to be essential for the human, in 
14 frequently used non-prescription and prescription 
pediatric oral medications. The medications selected 
for study were representative of the major categories of 
oral liquids that are frequently administered to infants. 
The categories were oral multivitamin drops, iron drops, 
pain and fever medications, fluoride supplements, an-
tibiotics, and pediatric electrolyte solutions.
Elemental concentrations were determined by in-
ductively coupled plasma mass spectrometry (ICP-MS), 
which is the most sensitive and widely used analytical 
method by which to quantitate elements.10 This method 
combines a high-temperature (ICP) source with a mass 
spectrometer (MS). The ICP source atomizes the sample 
and then converts the atoms to ions, which are sepa-
rated and detected by the MS. For a more detailed 
description, visit http://crustal.usgs.gov/laboratories/
icpms/intro.html. The use of ICP-MS provided the op-
portunity to concurrently quantify numerous elements 
in addition to aluminum, cadmium, and lead. These are 
summarized in Table 1.
Materials and Methods
The studied medications, listed in Table 2, were pur-
chased from the Kentucky Clinic Pharmacy (Lexington, 
KY). National Institute of Standards and Technology 
traceable multielement standards were purchased 
from Inorganic Ventures (Christiansburg, VA). Trace 
metal–grade nitric acid was purchased from Fisher 
Scientific (Pittsburgh, PA).
Sample Preparation. The procedures used to pre-
pare pharmaceuticals as homogeneous liquids for 
ICP-MS element quantification are noted below. With 
the exception of the oral electrolyte solution, each 
sample was independently prepared in triplicate. A 
sample aliquot of 0.75 mL was pipetted into a 15-mL 
metal-free centrifuge tube from VWR International 
(Radnor, PA) with 0.75 mL of nitric acid. It was open 
vessel digested in a CEM MARS Xpress microwave 
following US EPA method 3015A, then diluted to 15 mL 
with 18.2 mΩ-cm water. Immediately prior to analysis, 
samples were diluted 5-fold with 18.2 mΩ-cm water, and 
an internal standard solution from Inorganic Ventures 
(Christiansburg, VA), containing approximately 1 mg/L 
each of scandium, germanium, yttrium, rhodium, indium, 
terbium, and bismuth was added. The oral electrolyte 
solution was diluted 5- and 10-fold with 18.2 mΩ-cm 
Table 1. Other Elements Determined in this Study
Reference Element Potential Adverse Effects
Elements that are essential micronutrients or beneficial to the human
 11 Barium Disruption of cardiac rhythm
 12 Chromium Pulmonary and myocardial toxicity
 13 Cobalt Thyroid gland enlargement
 14 Copper Liver damage
 15 Magnesium Diarrhea, nausea, and abdominal cramping
 16 Manganese Neurological deficits
 17 Nickel Gastrointestinal disturbances
 18 Selenium Peripheral anesthesia and pain
 19 Vanadium Diarrhea and hypoglycemia
 20 Zinc Gastrointestinal and hematological effects
Elements lacking evidence of essentiality for the human
 21 Silver Gray or blue-gray discoloration of the skin, “argyria”
 22 Strontium Bone growth problems
 23 Uranium Nephrotoxicity
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water in triplicate, and both dilutions were analyzed. 
Samples were analyzed by a 7500cx quadrupole ICP 
mass spectrophotometer from Agilent Technologies 
(Santa Clara, CA).
Analysis. Calibration and verification were performed 
using 2 independent lots of IV-ICPMS-71A multielement 
standards from Inorganic Ventures. Pre-digestion spike 
recovery, which measures recovery during the diges-
tion procedure as well as analytical recovery, was de-
termined by adding 50 mcL of the 10 mg/L calibration 
standard to the sample before digestion. Postdigestion 
spike recovery, which measures analytical recovery, 
was determined by adding 10 mcL of 10 mg/L standard 
to 5 mL of the 5-fold diluted sample.
Care was taken to minimize metal contamination, 
including use of metal-free centrifuge tubes, trace 
metal–grade nitric acid, and 18.2 mΩ-cm water. All di-
lution procedures were conducted in an International 
Standards Organization class 100 laminar flow hood. 
The method detection limit was calculated as 3 times 
the standard deviation of 7 reagent blanks. Analytical 
results not above the method detection limit were 
considered to be below the detection limit and were 
assigned 50% of the method detection limit.
Calculation of Element Amount. The following 
procedure was used to compare the concentration of 
each element in the studied medications to exposure 
guidelines. To determine if the amount of each element 
in each medication might present a health risk, its in-
take for 1 week from administration of the medication’s 
Table 2. The Pediatric Oral Medications Studied
Product Manufacturer National Drug Code
Pediatric Electrolyte Oral Electrolyte Solution Leader (distributed by Cardinal Health, Dublin, OH) 37205-0221-08
Q-PAP Infants’ Drops Acetaminophen Qualitest Pharmaceuticals (Huntsville, AL) 0603-0838-73
Children’s Māpap Acetaminophen Liquid Major Pharmaceuticals (Livonia, MI) 0904-1985-20
Infants’ Advil Concentrated Drops Pfizer Inc (Madison, NJ) 0573-0191-20
Children’s Ibuprofen Oral Suspension, USP Major Pharmaceuticals (Livonia, MI) 0904-5577-20
Penicillin V Potassium for Oral Solution, USP Teva Pharmaceuticals (Sellersville, PA) 0093-4127-74
Amoxicillin for Oral Suspension, USP Sandoz (Princeton, NJ) 0781-6041-46
Infants’ Gas Relief Drops Leader (distributed by Cardinal Health, Dublin, OH) 37205-119-10
Fer-iron drops Rugby (Duluth, GA) 0536-0710-80
Tri-vitamin Drops Rugby (Duluth, GA) 0536-8501-80
Polyvitamin Drops Rugby (Duluth, GA) 0536-8450-80
Poly-Vita Drops Major Pharmaceuticals (Livonia, MI) 0904-5099-50
Tri-Vit with Fluoride 0.25-mg Drops Qualitest Pharmaceuticals (Huntsville, AL) 0603-1785-47
Sodium Fluoride Drops Sancilio & Company Inc (Riviera Beach, FL) 44946-1032-8
USP, United States Pharmacopoeia
Table 3. Exposure Guidelines for Element Intake
Adequate intake Established when evidence is insufficient to develop an RDA and is set at a level 
assumed to ensure nutritional adequacy 
Minimal risk level Estimate of exposure level posing a minimal risk to humans 
Oral reference dose Obtained from the US EPA Integrated Risk Information System. A daily exposure estimate 
to the human population that is likely to be without an appreciable risk of deleterious 
effects during a lifetime 
Permissible daily exposure Determined by the USP. It is expressed in mcg/day for the administration of drug 
products to an average 50-kg person 
Permitted daily exposure Determined by the FDA. It is the maximum acceptable intake of elemental impurity in 
pharmaceutical products per day
Provisional tolerable weekly 
intake 
An endpoint used for food contaminants, such as heavy metals with cumulative 
properties, representing permissible human weekly exposure
Recommended dietary 
allowance 
Average daily intake sufficient to meet the needs of 97% to 98% of healthy individuals
Tolerable upper intake level Maximum daily intake unlikely to cause adverse health effects 
EPA, Environmental Protection Agency; FDA, Food and Drug Administration; RDA, recommended daily allowance; USP, United States Pharmacopeia
Pediatric Oral Medication Element ContentYokel, RA et al
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Table 4. Exposure Guidelines of the Studied Elements
Element Guideline Guideline value Guideline 
intake*
Reference
Aluminum Provisional 
tolerable weekly 
intake
2 mg/kg 15,200 The Joint Food and Agriculture Organization of the 
United Nations, World Health Organization Expert 
Committee on Food Additives, for all Al compounds 
in food25 
Barium Permitted daily 
exposure
1,400 mcg 9,800 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Oral reference 
dose
0.2 mg/kg/day 10,640 The US EPA Integrated Risk Information System, for 
chronic oral exposure based on an animal study26 
Cadmium Permissible daily 
exposure
25 mcg/day for a 
50-kg person
26.6 USP <232>
5 mcg 35 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Oral reference 
dose
1 mcg/kg/day 53.2 US EPA Integrated Risk Information System27 
Chromium Adequate intake 0.2 mcg/day 1.4 The NIH Office of Dietary Supplements, for zero to 
6- mo-old28 
Permitted daily 
exposure
10,700 mcg 74,900 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Cobalt Permitted daily 
exposure
50 mcg 350 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Copper Permissible daily 
exposure
1000 mcg/day for 
a 50-kg person
1,064 USP <232>
Adequate intake 200 mcg/day 1,400 The US Department of Agriculture Food and 
Nutrition Information Center recommended dietary 
allowance for zero to 12-month-old 29 
Permitted daily 
exposure
3,000 mcg 21,000 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Lead Permissible daily 
exposure
5 mcg/day for a 
50-kg person
5.32 USP <232>
Permitted daily 
exposure
1 mcg 7 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Magnesium Recommended 
daily allowance
30 mg for zero to 
6-month-old
210,000 The NIH Office of dietary supplements 
recommended dietary allowance for zero to 
6-month-old15 
Manganese Tolerable upper 
intake level
2 mg/day for 1 to 
3-yr-old
8,960 No tolerable upper intake level has been established 
for zero to 12-month-old by the US Department of 
Agriculture Food and Nutrition Information Center. 
The value for 1 to 3-yr-old was adjusted for the 
weight of 6-month-old29
Nickel Permissible daily 
exposure
500 mcg/day for 
a 50-kg person
532 USP <232>
Permitted daily 
exposure
200 mcg 1,400 The US FDA Q3D Elemental Impurities Guidance for 
Industry 2
Selenium Tolerable upper 
intake level
45 mcg/day 315 The NIH Office of Dietary Supplements for zero to 
6-month-old30 
Permitted daily 
exposure
150 mcg 1,050 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
EPA, Enviormental Protection Agency; FDA, Food and Drug Administration; NIH, National Institutes of Health; US, United States; USP, United 
States Pharmacopoeia
*as mcg/wk for a 7.6 kg child
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maximum recommended daily dose to 6-month-olds 
was calculated. Calculations were based on 7.6 kg, 
the average weight of a 6-month-old.24 The calculated 
intake was compared to a guideline for exposure to 
that element. There is no single source or exposure 
guideline for all 16 elements determined in this study. 
Guidelines were obtained from multiple sources. They 
are described in Table 3. Guideline values for the stud-
ied elements are listed in Table 4. Given that there is 
more than one guideline for some of the tested ele-
ments, we compared the intake of that element by a 
7.6-kg infant for 1 week to the lowest guideline value.
Results
Table 5 reports the pre- and postdigestion spike 
recovery results of the 16 studied elements. Spike re-
covery was variable, as low as 65% to 68% for lead and 
uranium and as high as 184% for selenium. Deviations 
from 100% recovery are addressed in the “Discussion” 
section.
Table 6 shows the exposure guideline intake for each 
element, selected from the guidelines summarized in 
Table 4, the concentration of each studied element in 
each medication, and the percentage of the lowest 
exposure guideline for 1 week’s intake of the pediatric 
oral medication by a 7.6-kg child. The results provide 
toxic and essential trace element concentrations in 
commonly administered pediatric oral medications 
that pharmacists and others can incorporate into cal-
culations of total element intake. If consumed at the 
maximum recommended dose for 1 week, which is 
much longer than its typical period of use, the pediatric 
electrolyte solution would provide the greatest amount 
of the greatest number of elements: barium, copper, 
magnesium, silver, strontium, uranium, and zinc. It would 
provide 200% of the Institute of Medicine’s tolerable 
upper intake concentration of zinc. Fer-iron drops 
had the highest concentration of 9 of the elements: 
aluminum, chromium, cobalt, copper, lead, manga-
nese, nickel, vanadium, and zinc. However, given the 
small amount of this medication that is administered, 
it did not always present the greatest percent of the 
intake guideline. The greatest percent of the intake 
guideline of aluminum would come from the Fer-iron 
drops, followed by the penicillin V potassium solution. 
Both would deliver less than 1% of the weight-adjusted 
provisional tolerable weekly intake of aluminum.25 The 
greatest amount of cadmium would be delivered by 
the Infant’s Advil concentrated drops, followed by the 
pediatric electrolyte solution, both delivering less than 
2% of the USP guideline, adjusted for the weight of a 
6-month-old infant. The penicillin V potassium for oral 
solution product would deliver the greatest percent-
age of the 6-month-old weight-adjusted USP guideline 
for lead of 4.4%, followed by the pediatric electrolyte 
solution that would deliver 2.7% of the guideline. Many 
of the medications provide adequate intake of the 
essential micronutrient chromium, 0.2 mcg/day, the 
guideline used in Table 6, but none approach the FDA’s 
permitted daily exposure for acceptable intake of 10,700 
mcg/day. None of the medications provided amounts 
close to 100% of the recommended daily allowance 
of magnesium, the greatest being the 4% provided by 
the pediatric electrolyte solution. Similarly, they do not 
provide close to 100% of the recommended dietary 
allowance for zero to 12-months-old of 200 mcg/day 
copper.29 The greatest contribution of copper, 3.5%, 
would be provided by the pediatric electrolyte solution.
Many of the medications contain FD&C color addi-
Table 4. Exposure Guidelines of the Studied Elements (cont.)
Element Guideline Guideline value Guideline 
intake*
Reference
Silver Oral reference 
dose
0.005 mg/kg/day 266 US EPA Integrated Risk Information System oral 
reference dose31 
Permitted daily 
exposure
150 mcg 1,050 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Strontium Oral reference 
dose
0.6 mg/kg/day 31,920 US EPA Integrated Risk Information System32 
Uranium Minimal risk level 0.0002 mg/kg/
day
10.6 For 15 to 365 day oral exposure23
Vanadium Permissible daily 
exposure
100 mcg/day for a 
50-kg person
106 USP <232>
Permitted daily 
exposure
100 mcg 700 The US FDA Q3D Elemental Impurities Guidance for 
Industry2
Zinc Tolerable upper 
intake level
4 mg/day 28,000 The US Department of Agriculture Food and Nutrition 
Information Center, for zero to 6-month-old29
EPA, Enviormental Protection Agency; FDA, Food and Drug Administration; NIH, National Institutes of Health; US, United States; USP, United 
States Pharmacopoeia
*as mcg/wk for a 7.6 kg child
Pediatric Oral Medication Element ContentYokel, RA et al
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tives that have maximum allowable concentrations of 
chromium, lead, and manganese of 50, 10, and ≤ 100 
mg/L, respectively,33 as well as artificial and natural 
flavors that might contain metals. In the absence of 
declaration of the amount of FD&C color additives and 
flavors added, it cannot be determined if FD&C color 
additives significantly contribute to the measured metal 
concentrations in these products.
Discussion
The results shown in Table 6 indicate that commonly 
administered medications given in maximum therapeu-
tic doses to 6-month-olds would generally result in the 
intake of trace elements well below their adverse effect 
exposure guidelines, shown in Table 4. These findings 
suggest there is no concern for element toxicity from 
these medications alone. The results also show that 
the medications do not significantly contribute to the 
required intake for essential elements, with the excep-
tion of chromium.
There are reports of concentrations of some of the 
trace elements that were measured in the present study 
in medicines given to infants and young children, which 
can be compared to the present results. The median 
aluminum concentration in 5% glucose solutions was 
5 ng/g.9 The aluminum concentration has been re-
ported in numerous drugs,34,35 but in only 3 medications 
similar to those used in the present study. The median 
aluminum concentration in electrolyte and flavored 
electrolyte solutions was 5 ng/g, comparable to the 
6.2 mcg/L of the present study.9 A ferrous sulfate solu-
tion contained 130 mcg/L aluminum.34 The aluminum 
concentration was reported to be 11 and 36 mcg/L in 2 
lots of Poly-vi-sol,36 compared to 4900 and 3800 mcg/L 
in 2 generic equivalent products in this study. None of 
these medications would be expected to deliver more 
than 1% of aluminum’s provisional tolerable weekly 
intake.25 Although it has been noted that medications 
contribute to pediatric lead poisoning,37 median lead 
concentrations in 5% glucose, electrolyte, and flavored 
electrolyte solutions were 0.14, 0.16, and 0.08 ng/g, 
respectively,9 and were very low in the present study. 
Cadmium concentration in these 3 classes of products 
was 0.01 ng/g.9
In addition to commonly used oral medications, other 
sources can contribute the elements of the present 
study to their total intake by infants and young children. 
The US FDA permits aluminum in vaccines as an ad-
juvant, not to exceed 0.85 to 1.25 mg in an individual 
dose.38,39 The aluminum concentration in parenteral 
nutrition components,5 infant formula,40 and foods41 
has been reviewed. Milk-based, cereal-based, and 
mixed infant formula from Turkey averaged ~7 ng/g 
lead, whereas cadmium concentrations were ~1, 9, and 
5 ng/g, respectively.42 Calculated daily intake of lead 
and cadmium from these infant formulae was below 
their acceptable intake limits. In contrast, 8 of the 63 
formulae samples were calculated to deliver more alu-
minum than the provisional tolerable weekly intake of 2 
mg/kg.25 Several of the infant formulae delivered more 
than the recommended adequate intake amounts of the 
essential metals manganese and chromium, but none 
exceeded the tolerable upper intake concentration of 
manganese29 or permitted daily exposure of chromium.2 
The infant formula with the highest cobalt concentra-
tion was calculated to deliver slightly more than the 
permitted daily exposure of cobalt.2 There was sufficient 
chromium and zinc contamination of parenteral nutrition 
components to exceed administration recommenda-
tions,43 but not to exceed the parenteral permitted daily 
exposure of chromium.2 The largest total delivered zinc, 
0.2 mg/kg/day parenterally, would slightly exceed the 
tolerable upper oral intake concentration of 4 mg/day 
for a zero to 6-month-old,29 for this metal that is ~20% 
to 30% absorbed in persons with adequate nutritional 
concentrations.20
Extensive PubMed and SciFinder searches did not 
uncover any further reports of the contents of the 16 
elements of the present study in conventional medica-
tions intended for infant and pediatric human use.
There are some limitations to this study. As noted 
in the “Results” section, spike recovery was variable 
and deviated from 100% for several metals. There was 
little difference between the pre- and postdigestion 
spike recoveries, suggesting the primary contributor to 
recovery deviation was analytical recovery rather than 
recovery during the digestion procedure. The common 
Table 5. Pre and Postdigestion Spike Recovery 
Results*
Predigestion Postdigestion
Aluminum 95 ± 24 89 ± 5
Barium 106 ± 9 113 ± 2
Cadmium 110 ± 15 120 ± 6
Chromium 94 ± 17 90 ± 2
Cobalt 87 ± 17 90 ± 5
Copper 94 ± 19 115 ± 4
Lead 68 ± 11 72 ± 4
Magnesium 96 ± 7 92 ± 8
Manganese 83 ± 14 90 ± 5
Nickel 101 ± 16 113 ± 2
Selenium 174 ± 51 184 ± 22
Silver 88 ± 13 111 ± 2
Strontium 100 ± 12 110 ± 8
Uranium 65 ± 11 72 ± 4
Vanadium 76 ± 50 89 ± 6
Zinc 103 ± 16 140 ± 17
*Data presented as mean percent ± standard deviation
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confounder for samples with low spike recovery, such 
as lead and uranium, seemed to be fluoride. Several 
metals form insoluble fluorides; the ratio between fluo-
rine and the metal needs to be carefully controlled in 
these cases.
The spike recovery of some metals, notably sele-
nium, was high. This is probably due to a polyatomic 
contribution from argon chloride, 37Cl40Ar. In the plasma 
ion source of the ICP-MS a small percentage of the 
ions exist as polyatomic species rather than individual 
atoms. Because an argon plasma was used, polyatomic 
species containing argon were abundant.44 In the case 
of selenium, the monitored m/z ratio (mass/charge ratio, 
in the case of an ion with a charge of +1, which in this 
case is >98% of the ions, is equal to the mass) of 77 
for 77Se overlaps with the polyatomic species 37Cl40Ar. 
Chromium is similarly subject to severe polyatomic 
interferences. The monitored m/z ratios for chromium 
of 52 and 53 overlap with 12C40Ar and 13C40Ar.
The recovery deviation results indicate that better 
quantification, digestion, and analysis methods may 
need to be optimized for each type of medication 
based on overall composition. There are no certified 
reference materials for trace element concentrations in 
pharmaceuticals that could be used to validate these 
results, so validation using an independent analytical 
technique or isotope dilution mass spectrometry would 
be helpful. Therefore, these results should be consid-
ered semiquantitative.
Given that none of the medications were calculated 
to contribute more than 10% of the guideline value for 
adverse element exposure, with the exception of 2 
observations each for vanadium and zinc, the results do 
not support the hypothesis that commonly administered 
pediatric oral medications are sources of dangerous 
concentrations of the toxic metals and essential trace 
elements we analyzed. Although it is likely that other 
marketed generic and name-brand products would 
have different concentrations of the tested elements, 
with the exception of vanadium and zinc, they would 
have to have more than a 10-fold higher concentration 
to present an adverse element exposure. This could be 
tested by expanding the present study to include other 
marketed products. Furthermore, with the exception of 
chromium, the results show that none of the medica-
tions would contribute more than 10% of the guideline 
value for essential elements.
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